Segment Data

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Data

Segment Data

The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Prior to its spin-off on April 1, 2022, the Company reported the Diabetes Care business as an organizational unit within the Medical segment. As such, historical financial information of the Medical segment has been recast in the tables below to reflect the total segment revenues and revenues from continuing operations. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. See Note 2 for further information.

Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended December 31,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	620	$	419	$	1,039	$	620	$	476	$	1,096
Medication Management Solutions	564		142		706		484		143		627
Pharmaceutical Systems (a)	119		290		409		102		294		397
Total segment revenues	$	1,303	$	852	$	2,154	$	1,207	$	913	$	2,120
Life Sciences
Integrated Diagnostic Solutions	$	508	$	445	$	952	$	615	$	530	$	1,145
Biosciences	137		212		349		129		209		338
Total segment revenues	$	645	$	657	$	1,302	$	744	$	739	$	1,483
Interventional
Surgery	$	287	$	76	$	363	$	281	$	80	$	361
Peripheral Intervention	236		197		433		217		197		413
Urology and Critical Care	259		74		333		254		87		340
Total segment revenues	$	782	$	347	$	1,129	$	752	$	363	$	1,115
Total revenues from continuing operations	$	2,730	$	1,856	$	4,586	$	2,703	$	2,016	$	4,718

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Segment income for the three-month periods was as follows:

	Three Months Ended December 31,
(Millions of dollars)	2022		2021
Income from Continuing Operations Before Income Taxes
Medical	$	554	$	572
Life Sciences	433		534
Interventional	301		265
Total Segment Operating Income	1,288		1,371
Acquisition-related integration and restructuring expense	(44)		(34)
Net interest expense	(96)		(96)
Other unallocated items (a)	(667)		(642)
Total Income from Continuing Operations Before Income Taxes	$	481	$	600

(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.